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1  | INTRODUC TION
Gonadotropin is a hormone that controls ovarian function in women. 
Abnormal secretion of gonadotropin results in an ovulatory disorder 
that is a common cause of infertility in women. Since human meno-
pausal gonadotropin (hMG), which contains follicle stimulating 
hormone (FSH) and luteinizing hormone (LH), was established as a 
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Abstract
Purpose: To evaluate the optimized protocol of low dose follicle- stimulating hormone 
(FSH) therapy that has a starting dose of 50 IU/62.5 IU with a small increment dose 
(12.5 IU) for women with World Health Organization (WHO) II ovulatory disorder 
and unexplained infertility.
Methods: Anovulatory women with WHO group II ovulatory disorder (ovulation in-
duction [OI] patients, n = 29), and with an unexplained infertility (ovarian stimulation 
[OS] patients, n = 21) were enrolled. The protocol of low dose step- up FSH therapy 
was optimized for the starting dose as 50 IU (body mass index [BMI] < 20 group) and 
62.5	IU	(BMI	≥	20	group)	with	the	increment	dose	of	12.5	IU.	Study	outcomes	were	
ovulation, monofollicular development and other variables.
Results: In the OIpatients, the ovulation rate was 100% (BMI < 20 group) and 90.9% 
(BMI	≥	20	 group).	 Monofollicular	 development	 was	 80.0%	 (BMI	<	20)	 and	 77.3%	
(BMI	≥	20).	The	pregnancy	rate	was	60%	(3/5	BMI	<	20)	and	18.2%	(4/22	BMI	≥	20).	
There was no multiple pregnancy. In the OSpatients, the ovulation rate was 100%. 
Monofollicular	development	was	85.7%	(BMI	<	20)	and	76.6%	(BMI	≥	20).	No	preg-
nancy was achieved in the OSpatients.
Conclusion: Optimized protocol of low dose FSH therapy setting a starting dose 
50 IU/62.5 IU by BMI with an increment dose of 12.5 IU was safe and highly effec-
tive in WHO group II anovulatory patients. However, this protocol seemed uneffec-
tive for patients with unexplained infertility.
K E Y W O R D S
low dose FSH, ovarian stimulation, ovulation induction, polycystic ovary syndrome, WHO 
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with World Health Organization (WHO) group I and II ovulatory dis-
orders.1 Purified preparation of FSH was also generated as a drug 
for WHO group II patients who did not need additional LH activity 
because their serum levels of LH remained adequate for the follic-
ular development. Although hMG and FSH were derived from the 
urine of menopausal women, recombinant FSH has been generated 
using biotechnology and has contributed to the improvement of the 
quality and the clinical availability of the product. These gonadotro-
pin drugs are used not only for ovulation induction (OI) in ovulatory 
disorders but also for ovarian stimulation (OS) in unexplained infer-
tility2 and OS in assisted reproductive technology (ART).3
On the other hand, infertility treatment, especially gonado-
tropin therapy, has brought serious side effects such as multiple 
pregnancy and ovarian hyperstimulation syndrome (OHSS). In the 
1970s, multiple pregnancy and severe OHSS rate were reported to 
be 36.3% and 3.9%, respectively, in 41 clomiphene- resistant PCOS 
patients treated with hMG- hCG.4 Multiple pregnancy has a nega-
tive impact on maternal health and the long- term outcome of the 
infants, as well as imposing a significant burden on neonatal practice. 
OI by gonadotropin easily leads to multiple follicular development 
and multiple ovulation which are responsible for the multiple preg-
nancy. Controlling the serum FSH level suitable for monofollicular 
development is not easy because the negative feedback system does 
not work adequately in anovulatory patients, and therefore the dose 
of hMG or FSH often becomes excessive and multiple follicles de-
velop. Based on the FSH threshold concept,5 minimizing the dose 
of FSH seems to be effective in facilitating monofollicular growth 
and reducing the risk of multiple pregnancy associated with OI. Since 
a chronic low dose FSH regimen was reported in 5 PCOS women 
in 1984,6 this type of regimen for OI has been reported to reduce 
multiple pregnancy.7-10 In the low dose step- up regimen, the start-
ing daily dose of FSH was 37.5 IU, 50 IU or 75 IU. The daily dose 
was increased by almost half of the starting dose; 25 IU or 37.5 IU, if 
no follicle developed after 7 days of administration, or after 14 days 
in the “chronic” protocol. Dose increment was considered weekly 
usually up to 4 times. The incidence of multiple pregnancy follow-
ing OI is reported to be  5.7% in low dose FSH therapy.10 However, 
this percentage might not be sufficient in comparison with recent 
ART, where elective single- embryo transfer (eSET) has become 
common and the multiple pregnancy rate has markedly reduced to 
3.1% in fresh cycles and 3.2% in frozen cycles in 2015 in Japan.11,12 
Additionally, FSH or hMG, with or without intrauterine insemination 
(IUI), has been used for OS as an empiric therapy in patients with 
unexplained infertility who have normal FSH secretion.2 OS, inject-
ing FSH to women with unexplained fertility, results in higher serum 
levels of FSH allowing multiple follicular development, which might 
expand the chance of conceiving as well as increase a risk of multiple 
pregnancy.
There is evidence that women with a lower body mass index 
(BMI) are more likely to show an excessive ovarian response to OI, 
whereas women with a higher BMI generally require higher total 
gonadotropin doses for inducing follicular development and ovula-
tion.13 The devise used for subcutaneous self- injection (Gonalef® 
Pen; Merk Serono Co., Ltd., Tokyo, Japan) of recombinant FSH was 
recently renewed, and this has allowed us to adjust the FSH dose 
in smaller steps of 12.5 IU. In this study, we planned and tested an 
optimized protocol of FSH therapy that has an individualized starting 
dose based on BMI and a fine incremental doses as low as 12.5 IU for 
infertile women with an ovulatory disorder and unexplained infertil-
ity in order to facilitate a monofollicular ovarian response.
2  | MATERIAL S AND METHODS
2.1 | Study design
This study was a prospective interventional trial.
2.2 | Patients
Fifty infertile patients were enrolled in this study, including anovula-
tory women with WHO group II ovarian insufficiency for whom OI 
was indicated (OI patients, n = 29), and eumenorrheic women with a 
diagnosis of unexplained infertility for whom OS was indicated (OS 
patients, n = 21). These subjects were divided into groups by BMI, 
(BMI	<	20	groups	and	BMI	≥	20	groups)	for	selecting	the	initial	FSH	
dose in the treatment described below (Section 2.3.). Each patient 
received only one cycle of the low dose step- up FSH therapy in this 
study, because we believe that multiple cycles treatment to the same 
patient is not fair due to the dose individualization in the following 
cycles and/or dropout of the patients who experienced unfavora-
ble outcome in the first cycle preventing precise estimation of the 
protocol.
World Health Organization group II ovarian insufficiency con-
sisted of amenorrhea (amenorrhea more than 6 months), oligomen-
orrhea (menstrual cycle more than 38 days), and anovulatory cycles 
(normal cycle length of 25- 38 days without ovulation) which were 
diagnosed using the Japan Society of Obstetrics and Gynecology 
(JSOG) criteria.14 The OI group included 20 patients with polycys-
tic ovary syndrome (PCOS). Diagnosis of PCOS was made using the 
criteria of JSOG14, which means that the PCOS patients in this study 
also met the Rotterdam criteria.15
Unexplained infertility was defined as not having apparent 
causes of infertility such as ovarian, male, and tubal factors. The 
OS patients had a regular menstruation of 25- 38 days cycle with a 
biphasic pattern of basal body temperature, and had normal luteal 
function (mid- luteal progesterone [P4] concentration >5 ng/mL be-
sides luteal phase length >10 days before registration).16
Two of the OI patients enrolled were ineligible because they ap-
peared to have WHO class I ovarian insufficiency. Therefore, these 2 
patients were excluded, leaving 48 patients evaluable for the study. 
One of the 2 excluded patients was a 33- year- old woman with a BMI 
of 21.5 kg/m2 who had a baseline LH of 1.4 IU/L, FSH of 3.3 IU/L, 
and estradiol (E2) <10 pg/mL. She was treated with FSH at a starting 
dose of 62.5 IU and achieved successful ovulation and pregnancy 
without dose increase. The other patient excluded was a 29- year- old 
woman with a BMI of 21 kg/m2 who had a baseline LH of <0.1 IU/L, 
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FSH of 0.2 IU/L, and E2 of  <10 pg/mL. FSH was initiated at a start-
ing dose of 62.5 IU, but the patient failed to respond (no follicle 
≥10	mm	in	diameter)	despite	dose	escalation.
2.3 | Treatment schedule
Recombinant human FSH (Gonalef® Pen; Merk Serono Co., Ltd.) 
was administered subcutaneously by self- injection according to a 
newly designed low dose step- up regimen for OI or OS. The start-
ing dose of FSH was determined by BMI as 50 IU for women with 
a BMI <20 kg/m2 (BMI < 20 groups) and 62.5 IU for women with a 
BMI	≥	20	kg/m2	 (BMI	≥	20	 groups).	 Each	 patient	 started	 the	 daily	
self- injection of FSH between Days 3 and 6 of the first menstrual 
cycle after enrollment. If sufficient follicular development did not 
occur	 (no	 follicles	 ≥10	mm	 in	 diameter),	 the	 dose	 of	 FSH	 was	 in-
creased by 12.5 IU, which is the minimum dose in the device. If a 
follicle	≥10	mm	in	diameter	was	found,	daily	dose	was	not	increased.	
If the follicle did not reach 18 mm in diameter within a week after it 
reached 10 mm in diameter or genital bleeding occurred during the 
treatment, the cycle was canceled. A decision about dose increment 
was made every 7 days and up to 4 increases were permitted. If a 
follicle	≥10	mm	in	diameter	did	not	appear	during	the	35	days	of	in-
jection, the cycle was canceled due to no response. Follicular devel-
opment was monitored by transvaginal ultrasonography (US), which 
was performed on Day 7 of treatment and every 2- 4 days thereafter. 
When the mean diameter of the dominant follicle reached 18 mm, a 
single dose of 5000 IU of human chorionic gonadotropin (hCG) was 
administered	 to	 induce	ovulation.	 If	 4	or	more	 follicles	≥16	mm	 in	
diameter were detected by transvaginal US, FSH treatment was dis-
continued, and administration of hCG was cancelled to reduce the 
incidence of multiple pregnancy.17 Additionally, IUI was scheduled 
on the day after the hCG injection based on their own choice consid-
ering the couple’s convenience and the duration of infertility.
2.3.1 | Transvaginal ultrasonography
The ovaries and follicular development were evaluated using trans-
vaginal US with a 7.5 MHz transducer (Sonovista FX; Siemens 
Healthcare K.K., Tokyo, Japan). Ovarian volume per ovary (OVPO) 
was evaluated by the same gynecologist (T. M.) at the starting day 
of the FSH treatment and determined by the following formula: 
0.5 × length × width × thickness.18 OVPO associates with serum 
anti- Müllerian Hormone (AMH) level in PCOS,19 which reflects ovar-
ian reserve and could influence on the ovarian response to FSH. 
OVPO	≥10	cm3 was reported to be one of the definitive factors and 
had 100% specificity to distinguish PCOS.18 All of the patients with 
OVPO	≥10	cm3 in the present study had PCOS.
2.3.2 | Blood sampling and hormone assay
Blood samples were collected on the day of starting the treatment 
before the first FSH injection (initial; for measuring LH, FSH, E2, tes-
tosterone [T], and AMH), on the day of hCG injection (preovulatory 
phase; for measuring LH, FSH and E2), and after 7- 8 days from hCG 
injection (mid- luteal phase; for measuring P4). Serum LH and FSH 
concentrations were measured using chemiluminescence immuno-
assay assay kits (ARCHITECT® LH II and FSH; Abbott Japan Co., LTD, 
Tokyo, Japan). Serum E2 and P4 concentrations were measured using 
the electrochemiluminescence immunoassay kit (ECLusys® Estradiol 
II and Progesteron III; Roche Diagnostics, K.K., Tokyo, Japan). The 
serum AMH concentration was measured using the electrochemilu-
minescence immunoassay kit (ACCESS AMH; Beckman Coulter, Inc., 
Brea, CA, USA). Serum LH, FSH, and T concentrations were used for 
diagnosing PCOS as well as monitoring the hormonal status during 
the treatment.
2.4 | Study variables
2.4.1 | Demographic and clinical characteristics
Demographic profile (age, height, weight, BMI), history of infertility (du-
ration, previous treatment, the presence of male factor and tubal factor 
in order to diagnose unexplained infertility), serum levels of hormones 
(FSH, LH, E2, P4, T, and AMH), and transvaginal US finding including 
polycystic ovarian morphology and ovarian volume both of which are 
essential for the diagnosis of PCOS, were summarized.
2.4.2 | Outcomes of the treatment, 
efficacy, and safety
Treatment outcome was estimated by dose up times, total dose of FSH, 
and the days of FSH injection. Successful ovulation, clinical pregnancy 
(detectable gestational sac in the uterus by trasvaginal US), monofollic-
ular	development,	number	of	developing	follicles	(≥16	mm	in	diameter),	
hCG cancellation due to an excessive (4 or more developing follicles 
≥16	mm	in	diameter)	or	 insufficient	(no	follicles	≥10	mm	in	diameter)	
response to FSH, multiple pregnancy, moderate or severe OHSS, and 
other side effects such as genital bleeding during the cycle and throm-
boembolic events associated with severe OHSS.
2.4.3 | Demographic and baseline parameters 
influencing/predicting treatment outcomes in OI
The relationship between the number of developing follicles (0- 2) or 
daily dose of FSH that was effective to induce monfollicular devel-
opment (FSH threshold) and multiple factors, such as demographic/
baseline parameters and serum hormone concentrations during the 
study, was analyzed in OI patients. Thereafter, multiple regression 
analysis was tried using the factors that showed a significant rela-
tionship with the FSH threshold which is a final daily FSH dose in the 
cycle achieving monofollicular development.
2.5 | Statistical analysis
Difference in values between the groups were analyzed using 
Student’s t test, Welch’s t test, and Mann- Whitney’s U test after 
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considering the variance and distribution. An association between 2 
categorical variables of FSH dose increment was analyzed using the 
chi- squared test. Correlations between FSH threshold and variables 
were calculated using Spearman’s rank order analysis or Pearson 
correlation test. The correlation between FSH threshold and vari-
ables was examined using multiple regression analysis. XLSTAT 
2016.2 (ADDINSOFT, New York, NY, USA) with Microsoft® Excel 
for Mac 15.32 (Microsoft Japan Co., Ltd., Tokyo, Japan) was used 
for statistical analysis. All data are presented as mean + SD values. 
Statistical significance was defined as P < .05.
2.6 | Ethics
This study was approved by the Ethical Committee of Tokushima 
University Hospital (approval No. 2075) and written informed con-
sent was obtained from all the participants.
3  | RESULTS
Background data of the subjects are shown in Table 1. There was 
no	significant	difference	between	the	BMI	<	20	group	and	BMI	≥	20	
group in the OI or OS patients. Although this study did not intend 
to compare the data of the OI patients with the OS patients, sev-
eral elements in their background showed significant differences 
between them. The duration of infertility was longer in the OS pa-
tients than in the OI patients because anovulatory women in the OI 
would be aware that they had difficulty in conceiving, and therefore, 
would consult a clinic earlier than women with unexplained infer-
tility	 in	the	OS.	The	BMI	≥	20	group	 in	OS	had	significantly	higher	
mean age compared with the other 3 subgroups (P < .01). The OI pa-
tients	showed	relatively	larger	OVPO	especially	in	BMI	≥	20	patients	
(P < .01) and tended to have higher serum AMH concentration, 
because 20 of 27 in the OI patients were PCOS, having enlarged 
ovaries.	All	of	the	patients	with	OVPO	≥10	cm3 in the present study 
were PCOS patients.
As	for	the	administration	of	FSH	in	the	OI	patients,	the	BMI	≥	20	
group tended to be greater in the parameters than in the BMI < 20 
group regarding the number of FSH doses increased, the total dose, 
or the number of days of FSH treatment, although the differences 
were not significant (Table 2). The dose up times in OI were summa-
rized in Tables 3 and 4. Two or more dose increments were needed 
in	0%	(0/5)	of	the	BMI	<	20	group	and	22.7%	(5/22)	of	the	BMI	≥	20	
group	(Table	3).	When	BMI	≥	20	group	was	divided	into	3	subgroups	
by BMI, 2 or more dose increments were needed in 10.0% (1/10), 
28.6% (2/7), and 40.0% (2/5, both of these patients failed to respond 
to	FSH)	of	20	≤	BMI	<	25,	25	≤	BMI	<	30,	and	BMI	≥	30	subgroups,	
respectively	(Table	4).	However,	even	with	BMI	≥	30,	2	patients	did	
not require any dose increment. Difference between BMI subgroups 
was not significant by chi- squared test due to the low number of 
patients for the statistical analysis. On the other hand, in the OS 
patients, there was no significant difference between the BMI < 20 
group	and	the	BMI	≥	20	group	for	the	parameters	of	FSH	adminis-
tration (Table 2), and all the patients did not need 2 or more dose 
increments (Table 5).
As for the clinical outcome of the OI patients, ovulation rate 
was	100%	in	the	BMI	<	20	group	and	≥90%	in	the	BMI	≥	20	group	
(Table 6). In the 2 patients who failed to achieve ovulation, no 
follicle grew over 10 mm in diameter even after 3 or 4 times of 
FSH	dose	escalations.	The	number	of	developing	follicle	(≥16	mm	
in diameter) was distributed from 0 to 2. Monofollicular develop-
ment rate per cycle with developing follicle in the OI patients was 
80.0%	 in	 the	BMI	<	20	 group	 and	85.0%	 in	 the	BMI	≥	20	 group.	
Monofollicular development rate per all cycles including cycles 
with no follicular development was 77.3% in the BMI group and 
85.0%	in	the	BMI	≥	20	group.	The	mean	number	of	developed	fol-
licles was as small as 1.20 and 1.15 in the BMI < 20 group and the 
BMI	≥	20	group,	respectively.	Pregnancy	rate	was	60.0%	(3/5)	 in	
TABLE  1 Background of the subjects
Ovulation induction (n = 27) Ovarian stimulation (n = 21)
BMI < 20 (n = 5) BMI ≥ 20 (n = 22) BMI < 20 (n = 7) BMI ≥ 20 (n = 14)
Initial dose 50 IU 62.5 IU 50 IU 62.5 IU
Age (years) 32.4 ± 3.3 31.9 ± 2.9 33.4 ± 3.0 37.0 ± 2.6a
Duration of infertility (years) 0.90 ± 0.87 1.47 ± 1.54 4.88 ± 3.40b 5.45 ± 4.21c
Height (cm) 158.2 ± 7.4 156.3 ± 6.0 159.1 ± 4.7 156.4 ± 4.4
Weight (kg) 47.0 ± 4.3 64.1 ± 14.2 47.9 ± 2.7 61.1 ± 8.8
Body mass index (kg/m2) 18.7 ± 1.2 26.1 ± 5.0 18.8 ± 0.5 25.0 ± 3.8
OVPO (cm3) 9.64 ± 3.21d 7.72 ± 3.13 5.30 ± 2.13 6.28 ± 1.92
OVPO	≥	10	cm3 (%) 20.0 (1/5) 22.7 (5/22) 0 (0/6) 0 (0/12)
AMH (ng/mL) 12.90 ± 8.64 8.53 ± 5.17 3.45 ± 1.55 3.03 ± 1.34
AMH, anti- Müllerian hormone; BMI, body mass index; OVPO, ovarian volume per ovary; SD, standard deviation.
aP < .01 vs other groups (mean ± SD).
bP < .05 vs OI BMI < 20 (mean ± SD).
cP	<	.01	vs	OI	BMI	≥	20	(mean	±	SD).
dP < .05 vs OS BMI < 20 (mean ± SD).
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the	BMI	<	20	group	and	18.2%	 (4/22)	 in	 the	BMI	≥	20	group.	All	
7 pregnancies achieved in the OI patients were singleton. There 
was no cycle of hCG cancellation due to excessive response, and 
no incidence of moderate or severe OHSS and also no mild OHSS. 
The other adverse reaction to FSH was genital bleeding with no 
response of the ovary, which was reported in one patient receiving 
the OI treatment.
In the OS patients, ovulation rate was 100% in both the BMI < 20 
group	and	the	BMI	≥	20	group.	The	number	of	developing	follicle	
(≥16	mm	in	diameter)	was	distributed	from	1	to	3.	Monofollicular	
development rate in OS was 85.7% in the BMI < 20 group and 
78.6%	in	the	BMI	≥	20	group.	The	mean	number	of	developing	fol-
licles was as small as 1.14 and 1.36 in the BMI < 20 group and the 
BMI	≥	20	group,	respectively.	Ten	of	21	patients	received	IUI.	No	
patient in the OS patients became pregnant. There was no cycle of 
hCG cancellation due to excessive response, and no incidence of 
moderate or severe OHSS. Mild OHSS occurred in 1 patient, who 
was a 35- year- old woman with a BMI of 21.87 kg/m2. She had 3 
developing follicles with an ovarian size of 7.67 cm × 4.72 cm by 
initial FSH dose of 62.5 IU and thereafter hCG was injected. There 
was no other side effect in the OS patients.
Serum hormone levels during FSH treatment was depicted 
in Figure 1. The E2 level increased significantly from the start of 
FSH treatment (initial) to the day of hCG injection (preovulatory) 
in all of the BMI groups of both OI and OS (P < .05 or P < .01). No 
group showed an increase in FSH level during FSH treatment, and 
OI BMI < 20 group tended to decrease it (P < .1). The LH level in-
creased during FSH treatment in the OS groups and the difference 
was	significant	 in	the	OS	BMI	≥	20	(P < .05) group. Mid- luteal P4 
levels	of	OI	BMI	<	20,	OI	BMI	≥	20,	OS	BMI	<	20,	and	OS	BMI	≥	20	
were 14.8 ± 5.67, 21.83 ± 13.29, 16.56 ± 6.16, and 14.27 ± 8.41, 
respectively, and were not significantly different among these 
groups. All patients showed normal luteal function during the 
study cycle.
In order to find a factor that influenced ovarian response to FSH 
treatment in the OS patients, the relationship between the number 
 
Ovulation induction (n = 27) Ovarian stimulation (n = 21)
BMI < 20 
(n = 5)
BMI ≥ 20 
(n = 22)
BMI < 20 
(n = 7)
BMI ≥ 20 
(n = 14)
Initial dose 50 IU 62.5 IU 50 IU 62.5 IU
Dose up times 
(times) (Mean ± SD)
0.20 ± 0.40 0.91 ± 1.35 0.29 ± 0.45 0.07 ± 0.26
Total dose of FSH 
(IU) (Mean ± SD)
625.0 ± 216.8 1111.4 ± 867.3 553.6 ± 244.6 573.2 ± 133.4
Days of FSH injection 
(days) (Mean ± SD)
12.0 ± 3.6 15.5 ± 10.2 10.4 ± 3.9 9.1 ± 1.9
BMI, body mass index; SD, standard deviation.
TABLE  2 Administration of follicle- 
stimulating hormone (FSH)
TABLE  3 Dose up times in ovulation induction patients








BMI, body mass index.
aOne of the patients ended in no follicular development.
bOne of the patients ended in genital bleeding.
TABLE  4 Dose up times in the subgroups of body mass index 
(BMI)	≥	20	group	in	ovulation	induction	patients
Dose up times
20 ≤ BMI<25 
(n = 10)
25 ≤ BMI<30 
(n = 7)
BMI ≥ 30 
(n = 5)
≤1
0 7 4 2
1 2 1 1
≥2
2 0 1 0
3 1 0 1a
4 0 1 1b
aThis patient ended in no follicular development.
bThis patient ended in genital bleeding.
TABLE  5 Dose up times in ovarian stimulation patients








BMI, body mass index.
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of	developing	follicles	(≥16	mm	in	diameter)	and	various	factors,	such	
as demographic and baseline parameters, were analyzed (Table 7). 
As a result, BMI was the only factor showing a significant correla-
tion with the number of the developing follicles (r	=	−.410,	P < .05). 
Among the OI patients who achieved monofollicular development, 
the relationship between the final daily dose of FSH that was effec-
tive to induce monofollicular development (FSH threshold) and de-
mographic/baseline parameters was analyzed (Table 8). Body mass 
index was the only factor showing a significant correlation with the 
FSH threshold (r	=	−.503,	P < .05), whereas age almost reached sig-
nificance (r	=	−.428,	P = .053). When a multiple regression analysis 
was performed using a model with the FSH threshold as a response 
variable and with BMI and age as explanatory variables, there was 
no significant association between the FSH threshold and BMI or 
age (Table 9). On the other hand, no parameter was significantly cor-
related with the number of developing follicles in the OS patients 
based on Spearman/Pearson correlation analysis (data not shown). 
As for AMH, although several factors (OVPO, PCOS, baseline serum 
LH level, duration of infertility and age) showed a significant cor-
relation with the serum AMH level based on Spearman/Pearson 
correlation analysis in the OI patients (P < .05 or P < .01), none of 
the factors concerning FSH treatment (dose up times, initial and 
TABLE  6 Clinical outcome of the treatment
Ovulation induction (n = 27) Ovarian stimulation (n = 21)
BMI < 20 (n = 5) BMI ≥ 20 (n = 22) BMI < 20 (n = 7) BMI ≥ 20 (n = 14)
Initial dose 50 IU 62.5 IU 50 IU 62.5 IU
Ovulation (%) 100.0 (5/5) 90.9 (20/22) 100.0 (7/7) 100.0 (14/14)
Monofollicular development (%) 80.0 (4/5) 85.0 (17/20) 85.7 (6/7) 78.6 (11/14)
Number of developing follicles 
≥16	mm
1.20 ± 0.40 1.15 ± 0.36 1.14 ± 0.35 1.36 ± 0.72
No response (%) 0 (0/5) 9.1 (2/22) 0 (0/7) 0 (0/14)
hCG cancel (%) 0 (0/5) 9.1 (2a/22) 0 (0/7) 0 (0/14)
Pregnancy (%) 60.0 (3/5) 18.2 (4/22) 0 (0/7) 0 (0/14)
Multiple pregnancy (%) 0 (0/3) 0 (0/4) — —
OHSS (%)b 0 (0/5) 0 (0/22) 0 (0/7) 0 (0/14)
Other side effects (%) 0 (0/5) 4.6 (1c/22) 0 (0/7) 0 (0/14)
BMI, body mass index; hCG, human chorionic gonadotropin; OHSS, ovarian hyperstimulation syndrome; OVPO, ovarian volume per ovary; SD, stand-
ard deviation.
aCancel due to no follicular development.
bModerate or severe OHSS.
cGenital bleeding (Mean ± SD).
F IGURE  1 Hormonal transition 
during follicle- stimulating hormone (FSH) 
injection is depicted. A and B, showed 
data of ovulation induction (OI) for 
patients with World Health Organization 
(WHO) group II anovulation and C and D, 
showed data of ovarian stimulation (OS) 
for patients with unexplained infertility. 
FSH did not elevate during FSH injection 
in OI and OS. Data are presented as 
mean ± SE values; *P < .05 vs initial; 
**P < .01 vs initial; , E2; , LH;  
, FSH
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total doses, and duration of the treatment) were correlated with the 
serum AMH level (data not shown).
4  | DISCUSSION
Multiple pregnancy is a major side effect of gonadotropin therapy 
that is derived from multifollicular development due to injection of 
excessive dose of FSH. Low dose step- up regimen of FSH was con-
structed as a safe method for WHO group II anovulatory patients, 
and has contributed to reduce the incidence of multiple preg-
nancy. We designed the new fine protocol of low dose step- up 
FSH therapy to reduce multifollicular development and the rate of 
multiple pregnancy. As a result, this protocol was highly effective 
to achieve monofollicular development and completely avoided 
the cancellation of the cycle due to excessive response and the 
complications of multiple pregnancy and/or OHSS, while having 
high rates of ovulation and pregnancy in WHO group II anovula-
tory patients.
Principle of low dose step- up FSH therapy was supported by 
FSH threshold concept.5 In order to achieve monofolliclar develop-
ment, we have to control serum FSH level just above the thresh-
old level suitable only for the dominant follicle to grow. Otherwise, 
higher FSH level far from the threshold level allows the growth of 
non- dominant follicles. Therefore, starting dose should be less than 
the threshold and preferably close to it if predicted. Careful seeking 
of the threshold level during the FSH treatment, smaller increment 
dose is apparently preferable to avoid over dose. Both of starting 
dose and increment dose of FSH would be crucial factors in the low 
dose step- up protocol for monofollicular development. The new de-
vise of FSH self- injection has enabled us to use fine adjustment of 
FSH dose. We decided to use 50 IU or 62.5 IU as an starting dose 
and 12.5 IU as an increment dose. Doses of 62.5 IU and 12.5 IU have 
not ever been used in the protocols of low dose step- up FSH ther-
apy. Serum FSH level did not rise from initial to preovulatory phase 
during FSH injection, indicating that FSH level was controlled suit-
ably by our new protocol.
Phase II study of recombinant FSH (follitropin alfa, GONALEF®/
GONAL- f®; Merk Serono S.A.) in Japan was conducted with starting 
doses of 37.5 IU, 75 IU and 150 IU, with increment dose of 37.5 IU 
for WHO group II anovulatory women. Both of 37.5 IU and 75 IU 
TABLE  7 Relationship between the number of the developing 
follicles (0- 2) and other factors in ovulation induction patients
Correlation coefficient (r) P value
Significant correlation




Initial estradiol (pg/mL) .374 .062











Duration of infertility 
(years)
−.128 .515





















TABLE  8 Relationship between effective daily dose of follicle- 
stimulating hormone (FSH) and other factors in the cycles which 
single follicle developed in ovulation induction patients
Correlation coefficient (r) P value
Significant correlation
Body mass index (kg/m2) .503 .024
No significant correlation
Age (years) −.428 .053
Ovarian volume per 
ovary (cm3)
.312 .169
Initial FSH (IU/L) −.263 .253
Weight (kg) .220 .337















Duration of infertility 
(years)
.117 .601
Initial estradiol (pg/mL) −.111 .640
Type of irregular 
menstruation
−.048 .829
Preovulatory FSH (IU/L) .008 .975
Height (cm) .007 .976
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groups showed favorable results in this phase II study; the rates of 
ovulation and pregnancy were 86.0% and 15.8% in 37.5 IU group, 
and 95.1% and 18.0% in 75 IU group. Rate of monofollicular devel-
opment seemed higher in 37.5 IU group (64.9%) than in 75 IU group 
(50.8%), and rates of hCG cancellation and ovarian enlargement 
symptoms were lower in 37.5 IU group. However, because ovulation 
rate was lower and the days of FSH injection was longer in 37.5 IU 
group, 75 IU was selected as a starting dose for Japanese women 
in the phase II study.19 The phase III study of follitropin alpha was 
conducted adopting the starting dose of 75 IU with increment dose 
of 37.5 IU. Monofollicular development was achieved only in 33.3% 
of the patients, and the rates of hCG cancellation and OHSS were 
7.0% and 7.8%.20 Results of the phase II and III trials suggested that 
75 IU was somewhat excess as a starting dose for monofollicular de-
velopment. Based on these data, optimized starting dose seemed to 
be located between 37.5 IU and 75 IU, which was a reason why we 
selected 50 IU and 62.5 IU as starting doses using the recent device 
with every 12.5 IU steps adjustable. There is another preparation 
of recombinant FSH, follitropin beta (follistim®; MSD K.K., Tokyo, 
Japan; formerly known as Banyu Pharmaceutical Co., Ltd., Tokyo, 
Japan, and Schering- Plough Corporation, Osaka, Japan.), which has 
been unfortunately withdrawn from the market in Japan in March, 
2018. Phase II study of follitropin beta for Japanese women with 
WHO group II comparing the starting doses of 25 IU and 50 IU 
showed that 25 IU starting was insufficient because of lower ovu-
lation rate (41.2%), and 50 IU starting showed relatively better re-
sult (57.2%) (Phase II study in Japan, internal report of MSD). In the 
phase III study of follitropin beta in Japan with starting dose of 50 IU 
and increment dose of 50 IU, ovulation rate was satisfactory (83.0%) 
but monofollicular development was achieved only in 28.3% (Phase 
III study in Japan, internal report of MSD), presumably due to large 
increment dose as 50 IU. Therefore, increment doses of 25 IU and 
50 IU were compared in a low dose step- up protocol adopting a 
starting dose of 50 IU in another phase II study of follitropin beta in 
Japan. As a result, a 25 IU increment showed relatively higher rates 
of monofollicular development (39.3% vs 24.1%) and pregnancy 
(85.7% vs 75.9%) thn 50 IU increment although these differences 
were not statistically significant (Phase II study in Japan, internal re-
port of MSD). A similar study in Europe and Canada including 158 
women showed a significant result that the 25 IU increment group 
showed a significantly higher rate of monofollicular development 
(41.3% vs 21.8%) with fewer cancellations (5.0% vs 20.5%) than the 
50 IU increment group.21 Thus, increment dose of 50 IU seems too 
large and detract from the benefit of the favorable starting dose of 
50 IU. Recent report suggested that relatively small increment dose 
of 25 IU also detracts benefit of extremely low starting dose of 
25 IU that 15.8% of cycles was cancelled due to excessive response 
in spite of 62.6% of monofollicular development cycle.22 Therefore, 
we think an increment dose would be the most important factor to 
get the FSH threshold level. The increment dose of our new proto-
col was as small as 12.5 IU, being adjustable in the recent devise, 
and this small dose would bring better results than previously tested 
protocols. However, a small increment rationally has the potential to 
prolong the treatment days due to multiple increments required to 
reach the FSH threshold level. Therefore, we had to set a starting 
dose close to the FSH threshold which differs individually. Previous 
studies in Japan suggested that 75 IU seemed excessive as a starting 
dose and 50 IU was insufficient for some of the patients. In general, 
lean anovulatory patients respond well to FSH and obese patients 
did not do so. BMI, ovarian volume, and menstrual pattern were re-
ported to be independent predictive factors of the FSH threshold.23 
Especially, BMI is objective and easy to calculate. On the other hand, 
an intermediate dose between 50 IU and 75 IU is 62.5 IU that we can 
now set using the recent self- injection devise. We planned to use a 
starting dose as 50 IU for women with a BMI <20 and as 62.5 IU for 
women	with	a	BMI	≥20	in	the	new	protocol	coupling	with	a	smallest	
increment dose of 12.5 IU because lean women might respond well 
to 50 IU, and 62.5 IU might be excessive for them.
Our present data from the newly developed protocol with start-
ing dose of 50 IU or 62.5 IU with 12.5 IU increment showed supe-
rior clinical outcome to the data of follitropin alfa starting at 75 IU 
with a 37.5 IU increment and the data of follitropin beta starting at 
50 IU with a 25 IU increment previously reported in Japan for WHO 
II anovulatory women, as for ovulation rate, monofollicular develop-
ment, hCG cancellation, and incidence of side effects such as multi-
ple pregnancy and OHSS. The pregnancy rate seemed satisfactory 
and the number of days of injection was acceptable in most of the 
patients. Our data also seems better than those of the excellent con-
ventional low dose step- up regimens using urinary FSH: an ovulation 
rate of 72% and a monofollicular development rate of 73% reported 
by Hamilton- Fairley et al,7 ovulation rates of 73% or 71% and mono-
follicular development rates of 72% or 84% at starting doses of 75 IU 
or 52.5 IU reported by Homburg et al.10 Thus, an ovulation rate of 
90% and/or monofollicular development rate of 70% has been re-
ported in the literature as an achievement of the low dose step- up 
FSH therapy. Our new optimized protocol achieved a higher rate of 
monofollicular	 development	 (80.0%/85.0%	 [BMI	<	20/BMI	≥	20])	
with adequate conception rate (100.0%; 90.9%) with no hCG can-
cellation due to excessive response, no multiple pregnancy, or OHSS 
in patients with WHO group II ovulatory disorder, adding a further 






Age(years) −2.234 −.385 .094
Body mass index 
(kg/m2)
0.322 .114 .632
TABLE  9 The multiple regression 
analysis of the factors related to follicle- 
stimulating hormone threshold in 
ovulation induction group (n = 21)
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Frequent dose up of FSH for no response of the ovary results in 
a prolonged treatment period and brings disappointment to the pa-
tients.	 There	 were	 several	 OI	 patients	 in	 the	 BMI	≥	20	 group	 who	
required 2 or more dose up times. It seems that such patients were 
prevalent in higher BMI subgroups. However, more than half the pa-
tients of each BMI subgroup responded in initial step or one- time dose 
up step, indicating that starting doses of 50 IU in the BMI < 20 group 
and	especially	62.5	IU	in	the	BMI	≥	20	group	should	be	kept	to	pre-
vent injecting an excessive dose. We tried to find factors affecting a 
number of developing follicles or FSH threshold in monofollicular de-
velopment cycle. However, only BMI was a significant factor. To date, 
no effective prediction for FSH threshold has been reported although 
several factors are associated with FSH threshold.22,23 It is a future 
challenge to find an effective factor to predict FSH threshold other 
than BMI. Meanwhile, the low dose step- up method would be a realis-
tic method for ovulation induction in WHO group II patients to reach 
the FSH threshold during the treatment. For patients who require mul-
tiple dose up due to no response in the initial one or two cycles, ad-
justing the starting dose in the following cycle would be needed with 
reference to their own FSH threshold revealed in the initial cycle. Our 
optimized protocol with minimum increment dose and starting dose 
close to FSH threshold set by BMI would be a safe and effective mo-
dality, showing an insight for tactics modulating a low dose protocol.
Unexplained infertility is found in 15%- 40%24,25 of infertile cou-
ples. Ovarian stimulation by FSH has also been used as an empiric 
therapy for patients with unexplained infertility.2,3 Patients with un-
explained infertility have normal menstrual cycle, and OS by FSH 
frequently associated with multifollicular development, incidence 
of multiple pregnancy, and OHSS. In the recent study, 3 cycles of 
IUI with OS in patients with unexplained infertility brought 25/101 
(24.7%) singleton live births, 4/25 (13.8%) multiple pregnancy, and no 
cases of OHSS.26 Multiple pregnancy still seems to be problematic 
in OS treatment for unexplained infertility. In the present study, we 
tried mild stimulation in patients with unexplained infertility to pre-
vent multiple pregnancy. As a result, no patient required 2 dose up 
times or more, and all patients ovulated with predominant monofol-
licular	cycle	(85.7%	in	BMI	<	20	group	and	78.6%	in	BMI	≥	20	group).	
However, none of the 21 patients with unexplained infertility con-
ceived. After the study, all 21 patients continued OS with or without 
IUI, and only 1 patient conceived to date in a total of 75 cycles with 
4 cancelled cycles due to no response. It is assumed that mild stim-
ulation by our protocol is not suitable for patients with unexplained 
infertility. If multiple ovulation itself might enhance the chance of 
pregnancy, reducing the incidence of multiple pregnancy might be 
misguided, and elective single- embryo transfer in ART would be the 
only solution of the problem especially for patients with relatively 
long infertility period such as our subjects in this study.
In conclusion, low dose, step- up treatment with FSH starting 
with a BMI- based starting dose (50 IU for BMI < 20 and 62.5 IU for 
BMI	≥	20)	with	a	small	 increment	dose	(12.5	IU)	was	a	safe	and	ef-
fective protocol for OI in patients with WHO group II ovulatory dis-
order. In overweight and obese patients, who require 2 or more dose 
escalations, the starting dose of FSH for the following cycle should 
be individualized. On the other hand, mild stimulation using this pro-
tocol might not be useful for patients with unexplained infertility 
having relatively long infertility period.
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